Pediatric neurological and rare disease evaluation
Treatment options in Shanghai

Testing a parent or another relative sometimes helps determine whether the variant travels with particular clinical features or arose newly in the child. It is not automatically useful to test every family member. The genetics team should identify whose sample could change the interpretation and explain limitations, including that some genetic conditions are not expressed in every carrier. This evidence-gathering exercise differs from predictive testing that labels relatives at risk. A VUS should not itself trigger management changes for otherwise unaffected relatives.

The uncertain result should not, by itself, justify a gene-specific drug, surgery or a change to a relative's screening. However, treatment based on a child's established clinical problems can continue while the cause remains unresolved. Ask which current decisions depend on a confirmed molecular diagnosis and which are supported by the symptoms and examination already available. A medication response does not automatically prove that the variant caused the condition. Do not stop prescribed care while waiting for reclassification; discuss changes with the responsible clinical team.

For a child with symptoms crossing several specialties, Shanghai offers more than another reading of a single gene name. Children’s Hospital of Fudan University has brought clinical specialists together with molecular diagnostics, pathology and imaging in its undiagnosed-disease work. A multidisciplinary review can connect the child’s developmental and medical history to the variant, distinguish useful family testing from repeat testing that adds little, and identify care that should continue now. Explore our pediatric rare-disease assessment guide to see how such questions fit together. Learn more about Fudan’s pediatric multidisciplinary program.